Setara Biosciences has formed around a handful of assets from Actio Biosciences, which was acquired by Jazz Pharmaceuticals ...
Acumen will implement cash-saving strategies and assess its options after sabirnetug failed to beat placebo, leaving the ...
Alnylam shares dropped by a quarter on Thursday, with analysts suggesting the decline puts the RNAi specialist within range ...
TOKYO-- (BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) reported financial results for the second quarter of fiscal year 2026, ...
Raises Full Year 2026 Revenue and Cash Outlook on Continued Business Momentum Conference Call to Begin Today at 8:00 a.m. ET.
FEV1, FVC and other spirometric measures with 28 days of dosing in moderate to severe COPD patients. Fexlamose did not ...
Strong immunology and neuroscience sales fueled AbbVie’s latest quarterly beat as the pharma’s stock continues to hit ...
Reports Third-Quarter Diluted EPS of $2.37 on a GAAP Basis, an Increase of Over 100.0 Percent; Adjusted Diluted EPS of $3.82, ...
TJ101 is an investigational bispecific ADC targeting EGFR and B7-H3, incorporating a topoisomerase I inhibitor payload. The ...
The Marketing Authorization Application (MAA) is supported by positive Phase 3 RINGSIDE results demonstrating statistically ...
(Nasdaq: SRTS), a medical device company committed to providing highly effective, non-invasive treatments for oncological and ...
Focused on ensuring growth beyond Dupixent, Sanofi wants to acquire derisked assets that may benefit from the French pharma’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results